Pulmonx
Andrew Heppes is an experienced sales and business development professional in the medical and healthcare sectors, currently serving as Executive Territory Manager at Pulmonx Corporation since January 2019. Previously, Andrew held roles such as Director of Business Development at Thoracent and Business Development Consultant at Indi, where collaboration with senior leadership focused on advancing clinical studies for innovative pulmonary diagnostic solutions. Andrew's expertise spans various leadership positions, including Account Manager at Spiration, Inc., Regional Sales Director at Autologous Blood Technology, and Account Manager at St. Jude Medical, alongside an extensive tenure as Area Sales Director at Genzyme Biosurgery, cultivating a strong background in cardiovascular and pulmonary product sales. Andrew holds a Bachelor of Arts degree in Business from Baylor University, earned between 1989 and 1992.
This person is not in any teams
This person is not in any offices
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1